Comparative antitumor activities of halichondrins and vinblastine against human tumor xenografts

Journal of Experimental Therapeutics and Oncology

Volumn 1, Issue 2, 1996, Pages 119-125

  Fodstad, O ^a   Breistol K ^a   Pettit, G R ^c   Shoemaker, R H ^b   Boyd, M R ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b NATIONAL CANCER INSTITUTE   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Anti tumor activity; Halichondrins; Human xenografts; Natural product; Tubulin depolymerization

Indexed keywords

ANTINEOPLASTIC AGENT; ETHER DERIVATIVE; HALICHONDRIN B; HOMOHALICHONDRIN B; VINBLASTINE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; MOUSE; MOUSE STRAIN;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ETHERS, CYCLIC; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED STRAINS; NEOPLASM TRANSPLANTATION; VINBLASTINE;

EID: 17344374835     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Johnson IS, Armstrong JG, Gorman M, Burnett JP. The vinca alcaloids: a new class of oncolytic agents. Cancer Res 23: 1390-1427, 1963.
2. Himes RH, Kersey RN, Heller-Bettinger I, Samson FE. Action of the vinca alkaloids vincristine, vinblastine and desacetyl vinblastine amide on microtubules in vitro. Cancer Res 36: 3798-3802, 1976.
3. Dustin P. Microtubules. Berlin: Springer, 1984.
4. Hamel E. Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatin 10 and 15 and halichondrin B. Pharmacol Ther 55: 31-51, 1992.
5. Horwitz SB. Mechanism of action of taxol. Trends Pharm Sci 13: 134-136, 1992.
6. Boge TC, Himes RH, Vander Velde DG, Georg GI. The effect of the aromatic rings of taxol on biological activity and solution conformation: synthesis and evaluation of saturated taxol and taxotere analogues. J Med Chem 37: 3337-3343, 1994.
7. Boyd MR, Paull KD. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev Res 34: 91-109, 1995.
8. Hirata Y, Uemura D. Halichondrins-antitumor polyether macrolides from marine sponges. Pure & Appl Chem 58: 701-710, 1986.
9. Pettit GR, Herald CL, Boyd MR, et al. Isolation and structure of the cell growth inhibitory constituents from the Western Pacific marine sponge Axinella sp. J Med Chem 34: 3339-3340, 1991.
10. Pettit GR, Tan R, Gao F, et al. Isolation and structure of halistatin 1 from the Eastern Indian Ocean sponge Phakellia carteri. J Org Chem 58: 2538-2543, 1993.
11. Bai R, Paull KD, Herald CL, Malspeis L, Pettit GR, Hamel E. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. J Biol Chem 266: 15882-15889, 1991.
12. Luduena RF, Roach MC, Prasad V, Pettit GR. Interaction of halichondrin B and homohalichondrin B with bovine brain tubulin. Biochem Pharmacol 45: 421-427, 1993.
13. Boyd MR. The future of new drug development. In: Niederhuber JE, (ed.) Curr Therap Oncol 11-22, 1992.
14. Grever MR, Schepartz SA, Chabner BA. The National Cancer Institute: Cancer drug discovery and development program. Semin Oncol 19: 622-638, 1992.
15. Paull KD, Lin CM, Malspeis L, Hamel E. Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of different cytotoxicity data. Cancer Res 52: 3892-3900, 1992.
16. Hendriks HR, Langdon S, Berger DP, Breistøl K, Fiebig HH, Fodstad Y, Schwartsmann G. Comparative antitumor activity of vinblastine-isoleucinate and related vinca alkaloids in human tumor xenografts. Eur J Cancer 28A: 767-773, 1992.
17. Berger DP, Henss H, Winterhalter BR, Fiebig HH. The clonogenic assay with human tumor xenografts: evaluation, predictive value and application for drug screening. Ann Oncol 1: 333-341, 1990.
18. Fiebig HH, Atassi G, Boven E, et al. Preclinical phase II studies in human tumor xenografts: validation and first drug testing in a multicenter study. Invest New Drugs 7: 358-362, 1989.
19. Boven E, Winograd B, Berger DP, et al. Phase II preclinical drug screening in human tumor xenografts: A first European multicenter collaborative study. Cancer Res 52: 5940-5947, 1992.
20. Fodstad Ø, Aamdal S, McMenamin M, Nesland JM, Pihl A. A new experimental metastasis model in athymic nude mice, the human malignant melanoma LOX. Int J Cancer 41: 442-449, 1988.
21. Kjonniksen I, Nesland JM, Pihl A, Fodstad Ø. Nude rat model for studying metastasis of human tumor cells to bone and bone marrow. J Natl Cancer Inst 82: 408-412, 1990.
22. Pettit GR, Singh SB, Boyd MR, Hamel E, Pettit RK, Schmidt JM, Hogen F. Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5 and A-6. J Med Chem 38: 1666-1672, 1995.
23. Kjonniksen I, Breistol K, Fodstad Ø. Site-dependent differences in sensitivity of LOX human melanoma tumors in nude rats to dacarbazine and mitozolomide, but not to doxorubicin and cisplatin. Cancer Res 52: 1347-1351, 1992.
24. Hendriks HR, Plowman J, Berger DP, et al. Preclinical antitumor activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent. Ann Oncol 3: 755-763, 1992.